GAITHERSBURG, Md., Oct. 15 /PRNewswire/ -- MedImmune today announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
"Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases," said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. "Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma."
The schedule for MedImmune's nine posters and two oral presentations at the meeting, starting on Saturday October 17, is as follows:
About MedImmune
MedImmune, the worldwide biologics business for AstraZeneca PLC , has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.
SOURCE MedImmune
CONTACT: Media: Sidoney Atse for MedImmune, +1-301-398-5990
Web site: http://www.medimmune.com/
